New use for an old drug: Metformin and atrial fibrillation

Lal and colleagues(1) reported an integrative approach—combining transcriptomics, iPSCs, and epidemiological evidence—to identify and repurpose metformin, a main first-line medication for the treatment of type 2 diabetes, as an effective risk reducer for atrial fibrillation.

Detalles Bibliográficos
Autores principales: Vinciguerra, Manlio, Olier, Ivan, Ortega-Martorell, Sandra, Lip, Gregory Y.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Preview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798075/
https://www.ncbi.nlm.nih.gov/pubmed/36543101
http://dx.doi.org/10.1016/j.xcrm.2022.100875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798075/
https://www.ncbi.nlm.nih.gov/pubmed/36543101
http://dx.doi.org/10.1016/j.xcrm.2022.100875

Ejemplares similares